BioSpace News Archive

Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it will present at the Virtual Investor New to the Street Event on Wednesday, February 7, 2024 at 10:00 AM ET.

SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the issuance by the Canadian Intellectual Property Office of Canadian Patent No. 2814586.

The DeGregorio Family Foundation with support from the Torrey Coast Foundation Gastro Esophageal Investigator Network Initiative has awarded $75,000 to David E. Avigan, MD, of Beth Israel Deaconess Medical Center and Harvard Medical School for the development of a personalized dendritic cell/organoid-based vaccine for the treatment of gastric cancer.

Heart Test Laboratories, Inc. d/b/a HeartSciences, an artificial intelligence -powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced the appointment of Benjamin Glicksberg, Ph.D. to its Scientific Advisory Board.

Curemark, LLC announced the appointment of Chris Varelas to its Board of Directors. Mr. Varelas is a Co-founding Partner of Riverwood Capital, an investment firm focused on high-growth technology and technology-related companies.

Celularity Inc. announced expected net sales of its biomaterial products and biobanking businesses for the first quarter 2024 and the full year 2024, respectively, and reiterated its previously disclosed advanced biomaterial product commercial and development pipeline.

Be Biopharma, Inc. (“Be Bio”), a company pioneering the development of engineered B Cell Medicines (BCMs), today announced that it will present at the 20th Annual WORLDSymposium™ being held February 4-9, 2024, in San Diego, California.

Omeros Corporation announced the sale to DRI Healthcare Acquisitions LP, a wholly owned subsidiary of DRI Healthcare Trust, of an expanded interest in certain royalty payments based on net sales of OMIDRIA in the United States.

Agendia®, Inc., announced today that the first patient to use MammaPrint® as an enrollment biomarker for the DEBRA Trial is to be enrolled.

Co-Diagnostics, Inc. announced the list of events it has chosen to exhibit at or participate in during February, 2024, and which strategically align with the Company’s vision.